The Damo Institute for Advanced Research will open its doors in 2018. It will be mainly devoted to molecular therapeutics with an emphasis on the impact of treatment on cancer evolution. It will be headed at the start by Ariel Fernández.


Main Holdings
Tencent Holdings Ltd.
Alibaba Group Holding Ltd.
Baidu Inc.



Ariel Fernández (born Ariel Fernández Stigliano) is an Argentinian-American physical chemist and mathematician. He obtained a Ph. D. degree in Chemical Physics from Yale University and held the Karl F. Hasselmann Endowed Chair Professorship in Bioengineering at Rice University. He is currently involved in research and entrepreneurial activities at various consultancy firms. Ariel Fernández authored five books on translational medicine and biophysics, and published over 400 papers in professional journals. He also holds two patents in the field of biotechnology.


Publications related to the mission of the Institute:


​Ariel Fernández and L. Ridgway Scott: “Advanced modeling reconciles counterintuitive decisions in lead optimization”. Trends in Biotechnology, CELL Press 35, 490-497 (2017).
DOI: http://dx.doi.org/10.1016/j.tibtech.2016.12.003 

 Ariel Fernández: “Making targeted therapy compatible with checkpoint immunotherapy”. Trends in Biotechnology, CELL Press 35, 582-585 (2017). DOI: http://dx.doi.org/10.1016/j.tibtech.2017.02.008

 Ariel Fernández: “Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy”. Trends in Cancer, CELL Press 3, 675-677 (2017).
DOI: http://dx.doi.org/10.1016/j.trecan.2017.08.002

​​​​​Ariel Fernandez, Ph. D. 

Scientist/Consultant